Compare PRCT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCT | PHVS |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.8B |
| IPO Year | 2021 | 2020 |
| Metric | PRCT | PHVS |
|---|---|---|
| Price | $25.22 | $28.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $35.44 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 1.1M | 202.7K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $308,054,000.00 | N/A |
| Revenue This Year | $31.34 | N/A |
| Revenue Next Year | $24.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.22 | N/A |
| 52 Week Low | $19.35 | $13.81 |
| 52 Week High | $64.89 | $29.85 |
| Indicator | PRCT | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 58.00 |
| Support Level | $22.81 | $24.55 |
| Resistance Level | $28.57 | $29.82 |
| Average True Range (ATR) | 1.24 | 1.33 |
| MACD | 0.18 | 0.13 |
| Stochastic Oscillator | 65.64 | 71.47 |
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.